株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:潰瘍性大腸炎(UC) - 中国における医薬品の予測と市場分析

PharmaPoint: Ulcerative Colitis - China Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 300570
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
PharmaPoint:潰瘍性大腸炎(UC) - 中国における医薬品の予測と市場分析 PharmaPoint: Ulcerative Colitis - China Drug Forecast and Market Analysis to 2022
出版日: 2014年02月28日 ページ情報: 英文 88 Pages
概要

2012年〜2022年の潰瘍性大腸炎(UC)治療薬市場は、Johnson & Johnson(Simponi)、武田薬品工業(Entyvio)の参入によって大幅な成長が予測され、主要国(米国、EU5ヶ国、日本、カナダ)において、生物製剤による治療を受ける患者数が増加すると見込まれています。また、UCのブロックバスター薬(Remicade、Humira)が米国で特許失効となるため、バイオシミラー(バイオ後続品)の発売が、市場に影響を与える可能性があります。

当レポートでは、中国におけるUCの治療薬市場について調査分析し、疾病の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状
    • QOL

第4章 疾病の管理

  • 診断と治療の概要
    • 診断
    • 治療のガイドラインと主要な処方薬
    • 臨床診療
  • 中国

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
    • Remicade(infliximab)
    • Apriso(mesalamine)
    • Asacol HD(mesalamine)
    • Pentasa(mesalamine)
    • その他
  • バイオシミラー

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • アンメットニーズのギャップ分析
  • 病気の重症度と大腸癌バイオマーカーに基づく予後ツール
  • 難治性の予測因子

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤

第8章 市場の見通し

  • 中国

第9章 付録

図表

目次
Product Code: GDHC222CFR

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Overprescribing of medicines is common in China, as the revenue generated pays for the few quality hospitals that are available. To prevent overprescribing, the Chinese government recently cut the maximum price of about 1,200 commonly used drugs. Also, as a result of China's progress in reforming its healthcare system under the Five-Year Plan, basic medical coverage had reached more than 90% of the Chinese by the end of 2011.

Scope

  • Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in China from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the China Ulcerative Colitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
    • 3.2.1. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. China

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles. Major Brands
    • 5.3.1. Remicade (infliximab)
    • 5.3.2. Apriso (mesalamine)
    • 5.3.3. Asacol HD (mesalamine)
    • 5.3.4. Pentasa (mesalamine)
    • 5.3.5. Other Drug Classes Used in the Treatment of UC
  • 5.4. Biosimilars
    • 5.4.1. Introduction
    • 5.4.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 5.4.3. Biosimilars in the Immunology Community
    • 5.4.4. By the Numbers: Biosimilars in Development
    • 5.4.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Curative Therapy for Severe UC Patients
    • 6.2.2. Diagnostic Markers for Disease Severity
    • 6.2.3. Personalized Therapy
    • 6.2.4. A Replacement for Steroids
    • 6.2.5. Novel Oral Drug Formulations
    • 6.2.6. Preventative Medicine for Lowering the Associated Colorectal Cancer Risk
    • 6.2.7. Improved Management of Infectious Adverse Events
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools
  • 6.5. Predictors of Medically-Refractory Disease

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Market Outlook

  • 8.1. China
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed UC Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. Primary Research. Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Genetic Factors That Confer a Predisposition to UC
  • Table 2: Typical Symptoms of UC
  • Table 3: Truelove and Witts UC Severity Index
  • Table 4: UCDAI
  • Table 5: Treatment Guidelines for UC Used in the 10MM
  • Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013
  • Table 7: UC Management Country Profile - China
  • Table 8: Leading Treatments for UC, 2014
  • Table 9: Product Profile - Remicade
  • Table 10: Remicade SWOT Analysis, 2014
  • Table 11: Product Profile - Apriso
  • Table 12: Apriso SWOT Analysis, 2014
  • Table 13: Product Profile - Asacol HD
  • Table 14: Asacol HD SWOT Analysis, 2014
  • Table 15: Product Profile - Pentasa
  • Table 16: Pentasa SWOT Analysis, 2014
  • Table 17: Summary of Other Immunomodulators for UC, 2013
  • Table 18: Biosimilars Pipeline, 2013
  • Table 19: Overall Unmet Needs - Current Level of Attainment
  • Table 20: Corticosteroid Long-Term Side Effects
  • Table 21: Clinical Unmet Needs in UC - Gap Analysis, 2013
  • Table 22: Prognostic Markers in UC
  • Table 23: UC - Pre-Registration and Phase III Pipeline, 2014
  • Table 24: Comparison of Therapeutic Classes in Development for UC, 2014
  • Table 25: Sales Forecasts ($) for UC in China, 2012-2022
  • Table 26: Key Events Impacting Sales for UC in China, 2012-2022
  • Table 27: UC Market in China - Drivers and Barriers, 2012-2022
  • Table 28: Key launches for Ulcerative Colitis, 2012-2022
  • Table 29: Key Patent Expiries
  • Table 30: Annual Cost of Therapy for 5-ASAs ($)
  • Table 31: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: UC Disease Management Flowchart
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012-2022
  • Figure 4: Sales for UC in China by Drug Class, 2012-2022
Back to Top